Biocryst Pharmaceuticals (BCRX) Cash from Investing Activities Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | -478.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -478.16% |
| Mar 31, 2026 | -1,091.50% |
| Dec 31, 2025 | -569.11% |
| Sep 30, 2025 | 59.88% |
| Jun 30, 2025 | 1,289.34% |
| Mar 31, 2025 | -5.78% |
| Dec 31, 2024 | 162.50% |
| Sep 30, 2024 | -63.28% |
| Jun 30, 2024 | 87.13% |
| Mar 31, 2024 | 126.85% |
| Dec 31, 2023 | -136.87% |
| Sep 30, 2023 | 133.24% |
| Jun 30, 2023 | 80.46% |
| Mar 31, 2023 | -178.41% |
| Dec 31, 2022 | 794.38% |
| Sep 30, 2022 | -997.68% |
| Jun 30, 2022 | -2,263.37% |
| Mar 31, 2022 | -362.20% |
| Dec 31, 2021 | -151.93% |
| Sep 30, 2021 | 122.74% |